Oblique Therapeutics AB (publ). today announces that it has reached a key milestone in its aKRAS antibody program and achieved validation of its Abiprot® platform

Read our press release : Oblique Therapeutics announces achievement of key milestone in its aKRAS mAb program and Abiprot platform

Learn more about Abiprot: https://www.science.org/doi/10.1126/sciadv.abe6397